Evaluating only Navire Pharma’s profile at its peak — without knowing the outcome — the model ranked Unit economics as the #1 likely cause. Documented cause: Regulation.
Key Events Timeline
FOUNDING
Navire Pharma spun out of Bristol Myers Squibb to develop SHP2 inhibitor BBP-398 for RAS-driven cancers.
FUNDING
BMS commits additional $150M to Navire; Phase 1 data for BBP-398 shows promising tumor shrinkage in KRAS-mutant patients.
CEO CHANGE
BMS announces $1.5B restructuring; Navire's future flagged as uncertain despite active clinical enrollment.
SHUTDOWN
BMS dissolves Navire entirely; BBP-398 discontinued, 80 employees terminated, assets returned to BMS pipeline.
Full Analysis
Free · no account needed
Documented cause
Navire Pharma, a Bristol Myers Squibb spin-off focused on SHP2 inhibitor BBP-398 for oncology, was shut down by parent company BMS in December 2023 as part of a $1.5B cost-cutting restructuring. BMS had invested approximately $300M into Navire since its 2019 spinout. Despite promising Phase 1 monotherapy data, BMS CFO David Elkins cited portfolio prioritization, discontinuing BBP-398 development and terminating all 80 Navire employees with minimal severance notice.
Lesson
“Pharma spin-offs live and die by parent company capital allocation decisions, not scientific merit alone.”